Chemotherapy in elderly patients with colorectal cancer

Oncologist

Volumn 13, Issue 4, 2008, Pages 390-402

  Köhne, Claus Henning ^a   Folprecht, Gunnar ^b   Goldberg, Richard M ^c   Mitry, Emmanuel ^d   Rougier, Philippe ^d  

^a KLINIKUM OLDENBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Chemotherapy; Colorectal; Geriatric assessment; Irinotecan; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; UFT;

ADD ON THERAPY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; GERIATRIC ASSESSMENT; HUMAN; LIFE EXPECTANCY; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; GERIATRIC ASSESSMENT; HUMANS; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 43549126000     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0043     Document Type: Review

References (80)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-4091.
3. Ries LAG, Harkins D, Krapcho M et al., eds. Contents of the SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute, 2003. Available at http://seer.cancer.gov/csr/1975_2003/. Accessed September 27, 2006.
4. Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S cancer burden. Cancer 2002;94:2766-2792.
5. Minino AM, Heron MP, Murphy SL et al. Deaths: Final data for 2004. Natl Vital Stat Rep 2007;55:1-119.
6. Life Expectancy by Selected Ages Since 1946: Females. Paris, France: Institut National D'tudes Démographiques, 2007. Available at http://www.ined.fr/fichier/t_telechargement/11151/ telechargement_fichier_fr_telechargement_fichier_fr_sd2004_t69esp_fm.1.xls. Accessed December 12, 2007.
7. Life Expectancy by Selected Ages Since 1946: Males. Paris, France: Institut National D'tudes Démographiques, 2007. Available at http://www.ined.fr/fichier/t_telechargement/11152/ telechargement_fichier_fr_telechargement_fichier_fr_sd2004_t69esp_fm.1.xls. Accessed December 12, 2007.
8. Mitry E, Bouvier AM, Esteve J et al. Improvement in colorectal cancer survival: A population-based study. Eur J Cancer 2005;41:2297-2303.
9. Brenner H, Gondos A, Arndt V. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol 2007;25:3274-3280.
10. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-1389.
11. Sundararajan V, Mitra N, Jacobson JS et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with nodepositive colon cancer. Ann Intern Med 2002;136:349-357.
12. Potosky AL, Harlan LC, Kaplan RS et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002;20:1192-1202.
13. Lemmens VEPP, van Halteren AH, Janssen-Heijnen MLG et al. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol 2005;16:767-772.
14. Folprecht G, Cunningham D, Ross P et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 2004;15:1330-1338.
15. Sargent DJ, Goldberg RM, Jacobson SD et al.Apooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097.
16. Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
17. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. The Oncologist 2000;5:224-237.
18. Balducci L, Stanta G. Cancer in the frail patient. A coming epidemic. Hematol Oncol Clin North Am 2000;14:235-250.
19. Cassel CK. Money, medicine, and Methuselah. Mt Sinai J Med 1998;65:237-245.
20. Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999;130:945-950.
21. Hogan DB, Ebly EM, Fung TS. Disease, disability, and age in cognitively intact seniors: Results from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 1999;54:M77-M82.
22. Rockwood K, Stadnyk K, MacKnight C et al. A brief clinical instrument to classify frailty in elderly people. Lancet 1999;353:205-206.
23. Sastre J, Marcuello E, Masutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005;23:3545-3551.
24. Extermann M, Albrand G, Chen H et al. Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 2003;21:3214-3219.
25. Mitry E, Douillard JY, Van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-1017.
26. D'Andre S, Sargent DJ, Cha SS et al. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study. Clin Colorectal Cancer 2005;4:325-331.
27. Extermann M. Geriatric assessment with focus on instrument selectivity for outcomes. Cancer J 2005;11:474-480.
28. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
29. Aparicio T, Desrame J, Lecomte T et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003;89:1439-1444.
30. Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol 2002;3:289-297.
31. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458-1460.
32. McQuellon RP, Muss HB, Hoffman SL et al. Patient preferences for treatment of metastatic breast cancer: A study of women with early-stage breast cancer. J Clin Oncol 1995;13:858-868.
33. Saunders M, Iveson T. Management of advanced colorectal cancer: State of the art. Br J Cancer 2006;95:131-138.
34. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-237.
35. Köhne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-4865.
36. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004;5:2159-2170.
37. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 2007;25:4779-4786.
38. Barrueco J, Marshall J, Mitchell E et al. Safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study. Proc Am Soc Clin Oncol 2007;25:4076.
39. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
40. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
41. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
42. Rougier P, Mitry E, Cunningham D et al. Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA). Proc Am Soc Clin Oncol 2003;22:1072.
43. Mitry E, Tournigand C, André T et al. Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer - a pooled analysis of 254 patients included in 2 randomised trials. Proc Am Soc Clin Oncol 2004;22:3576.
44. Souglakos J, Pallis A, Kakolyris S et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 2005;69:384-390.
45. Folprecht G, Rougier P, Saltz L et al. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of three trials investigating 5-FU and irinotecan. Proc Am Soc Clin Oncol 2006;24:3578.
46. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
47. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
48. Chau I, Norman AR, Cunningham D et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004;91:1453-1458.
49. Schaaf L, Ichpurani N, Elfring G et al. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer Proc Am Soc Clin Oncol 1997;15:708.
50. Camptosar® (irinotecan hydrochloride injection) Prescribing Information. New York: Pharmacia & Upjohn Co, revised June 2006.
51. Venook AP, Enders Klein C, Fleming G et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14:1783-1790.
52. Schaaf LJ, Hammond LA, Tipping SJ et al. Phase I and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res 2006;12:3782-3791.
53. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
54. Tabah-Fisch I, Maindrault-Goebel F, Benavides M et al. Oxaliplatin/5 FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients. Proc Am Soc Clin Oncol 2002;21:556.
55. Rosati G, Cordio S, Tucci A et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 2005;69:122-129.
56. Levi F, Zidani R, Focan C et al. Age-independent benefit of chronotherapy with 5-fluorouracil, leucovorin, and oxaliplatin in patients with metastatic colorectal cancer within multicenter randomized phase III trials. Proc Am Soc Clin Oncol 2002;21:1431.
57. Escudero P, Verge V, Feliu J et al. A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:3114.
58. Feliú J, Escudero P, Losa F et al. A phase II study of capecitabine (X) in elderly patients (p) as 1st line treatment for patients (pts) with advanced of metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2004;22:3567.
59. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
60. Bollina R, Beretta G, Toniolo D et al. Capecitabine (C) and irinotecan (I) (CAPIRI): A good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first-line chemotherapy (CT). Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003;22:1332.
61. De Grève J, Koehne C, Hartmann J et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015. Proc Am Soc Clin Oncol 2006;24:3577.
62. Fuchs C, Marshall J, Mitchell E et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Proc Am Soc Clin Oncol 2006;24:3506.
63. Twelves CJ, Butts CA, Cassidy J et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: Post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005;5:101-107.
64. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282-289.
65. Feliú J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment of elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969-975.
66. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-2091.
67. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20:1759-1766.
68. Zeuli M, Nardoni C, Pino MS et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003;14:1378-1382.
69. Jensen SA, Lønborg JT, Sorensen JB. Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experience. Acta Oncol 2006;45:67-76.
70. Seymour MT, Maughan TS, Wasan HS et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. Proc Am Soc Clin Oncol 2007;25:9030.
71. Xeloda® (capecitabine tablets) Prescribing Information. Basel, Switzerland: Roche Pharmaceuticals Inc., revised April 2006.
72. Haller DG, Cassidy J, Clarke S et al. Tolerability of fluoropyrimidines appears to differ by region. Proc Am Soc Clin Oncol 2006;24:3514.
73. Hochster HS, Luo W, Popa EC et al. Phase II study of uracil-tegafur with leucovorin in elderly (≥ 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 2007;25:5397-5402.
74. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
75. Skillings JR, Johnson DH, Miller F et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc Am Soc Clin Oncol 2005;23:3019.
76. Sugrue MM, Kozloff M, Hainsworth J et al. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: Results from the BRiTE registry. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2007. Abstract 345.
77. Bouchahda M, Bachet J, Andre T et al. Cetuximab activity in elderly patients with extensively pretreated metastatic colorectal cancer. Presented at the 8th World Congress on Gastrointestinal Cancers, Barcelona, Spain, June 28-July 1, 2006.
78. ClinicalTrials.gov. Geriatric Oncology Consortium/Sanofi Aventis. Phase II study of oxaliplatin, capecitabine, and bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00120172. Accessed October 26, 2006.
79. Koeller J, McKibbin T, Kwan P et al. The impact of age on the overall chemotherapy (chemo) treatment (tx) of advanced (adv) colorectal (CRC) cancer in the community oncology setting (cos). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2007, Orlando, FL, January 19-21, 2007.
80. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. The Oncologist 2005;10(suppl 3):40-48.